单倍体与错配无关供者移植后环磷酰胺预防下的HCT结局比较
在MD安德森癌症中心接受移植后环磷酰胺预防的660例单倍体与195例错配无关供者HCT受者中,多因素分析显示单倍体供者相较MMUD组的总生存HR为1.20(95%CI 0.93-1.54;P=.16)。经IPTW、配对分析和CIBMTR外部验证一致。探索性分析显示>50岁单倍体供者组OS劣于<30岁MMUD受者(HR 1.91;95%CI 1.21-3.01;P=.005)。
要点
- 单倍体 vs MMUD的OS:HR 1.20(95%CI 0.93-1.54;P=.16),未达统计学显著。
- 供者年龄与OS呈非线性关联,作用较供者类型更突出。
- 探索性分析:>50岁单倍体供者组OS劣于<30岁MMUD受者(HR 1.91;95%CI 1.21-3.01;P=.005)。
核心结论
- 分析提示供者类型可能起作用,但供者年龄对OS的影响更突出。
- 作者认为供者类型的影响可能因供者年龄而异,需更大规模研究进一步阐明。
研究设计与样本
- 在MD安德森癌症中心接受HCT的660例单倍体受者与195例MMUD受者。
- 采用标准Cox比例风险模型、IPTW和配对分析,并纳入CIBMTR外部MMUD验证队列。
- 主要结局为总生存(OS)。
主要发现
- 多因素分析:单倍体供者相较MMUD组OS的HR为1.20(95%CI 0.93-1.54;P=.16)。
- 供者年龄与OS呈非线性关联。
- IPTW、配对分析和CIBMTR验证分析与上述结果一致。
- 探索性分析:>50岁单倍体供者组OS劣于<30岁MMUD受者(HR 1.91;95%CI 1.21-3.01;P=.005)。
局限性
- 原文指出需进一步研究,尤其需要更大规模队列,以阐明供者类型、供者年龄及HLA因素的复杂交互作用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Limited data exist comparing haploidentical and mismatched unrelated donor (MMUD) hematopoietic cell transplantation (HCT) with posttransplantation cyclophosphamide for graft-versus-host disease prophylaxis, especially considering donor age. Herein, we report the outcomes of 660 haploidentical and 195 MMUD HCT recipients treated at MD Anderson Cancer Center. Beyond standard Cox proportional hazards modeling, we used inverse probability of treatment weighting (IPTW) and matched-pair analysis, and performed additional analysis by incorporating an external MMUD validation cohort from the Center for International Blood and Marrow Transplant Research (CIBMTR). The primary outcome was overall survival (OS). In multivariable analysis, haploidentical donors had a hazard ratio (HR) of 1.20 (95% confidence interval [CI], 0.93-1.54; P = .16) compared with the MMUD group. Donor age showed a nonlinear association with OS. These findings were corroborated by IPTW, matched-pair analyses, and CIBMTR validation analyses. Exploratory analysis revealed inferior OS for older (age of >50 years) haploidentical donor group compared with younger (age of <30 years) MMUD recipients (HR, 1.91; 95% CI, 1.21-3.01; P = .005). Our analyses suggest that although donor type may play a role, there was a more prominent role for donor age in influencing OS. Moreover, our findings indicate a potential nuance wherein the impact of donor type may vary by donor age. Further research, particularly with larger cohorts, is needed to fully elucidate the complex and potentially interacting roles of donor type and donor age, along with HLA factors.
引用
- Aljawai YM, Ramdial J, Rondon G, et al. Outcomes of haploidentical vs mismatched unrelated donor HCT with posttransplant cyclophosphamide prophylaxis. Blood Adv. 2025. PMID: 40517414. doi:10.1182/bloodadvances.2025016236
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。